VERAXA Biotech (NASDAQ: VRXA) has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI), providing regulatory feedback that supports the proposed development strategy for its lead BiTAC®-TCE program. The advice, announced on July 20, offers early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan for its novel therapeutic platform. This milestone is expected to reduce development uncertainty by providing greater clarity before advancing toward clinical studies.
The BiTAC®-TCE platform is designed to engineer bispecific T-cell engagers, a class of immunotherapies that redirect a patient’s immune cells to attack tumors. VERAXA’s lead candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, highlighting its potential in oncology. The company believes the regulatory feedback from PEI, a key European authority, validates its approach and helps align its development plan with regulatory expectations.
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin. By obtaining early input on safety, tolerability, and non-clinical requirements, VERAXA can refine its development strategy and potentially accelerate timelines. The company noted that the feedback provides greater confidence in its biological rationale and planned assessments, which are critical for advancing BiTAC®-TCE toward first-in-human studies.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer. The company’s newsroom provides updates on its progress at https://ibn.fm/VRXA.
This development is significant as it marks a key step in translating VERAXA’s preclinical findings into clinical candidates. With regulatory guidance in hand, the company can proceed with more targeted non-clinical studies, potentially reducing costs and time to market. The positive feedback from PEI also signals that the BiTAC® platform’s mechanism of action is scientifically sound, which may bolster investor confidence in VERAXA’s pipeline.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s SEC filings. For full terms and disclaimers, visit http://IBN.fm/Disclaimer.
